Polymerase Inhibitors and the Use Thereof for the Treatment of Tumors

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new class of compounds known as polymerase inhibitors, particularly targeting DNA polymerase alpha. These compounds are specifically designed for the treatment of tumor diseases, especially various skin cancers such as actinic keratosis, basal cell carcinoma, and squamous cell carcinoma. Unlike existing therapies, these inhibitors selectively target cancer cells while sparing healthy cells and can be formulated in a variety of topical and systemic pharmaceutical preparations, offering improved efficacy and fewer side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of skin cancers like basal cell carcinoma, squamous cell carcinoma, and actinic keratosis, particularly in areas exposed to sunlight.
• Use in other tumor types, including internal cancers such as breast, colon, rectal, and bladder tumors.
• Topical therapy for precancerous skin lesions and keratoses.
• Secondary prevention (prophylaxis) to help prevent recurrence or progression of tumors after primary therapy.
• Development of new polymerase inhibitors for broader oncological or antiviral applications.
• Combination therapy with existing antitumor agents to enhance efficacy or reduce side effects of standard therapies.
• Potential veterinary applications in animals with skin or epithelial tumors.

BenefitsContent extracted from patent full text and abstract with AI.

• Selective toxicity: Greater preferential action against tumor cells with minimal effects on normal cells, reducing collateral damage and side effects.
• High efficacy: Demonstrates strong antiproliferative effect on a range of cancer cell lines, surpassing commonly used treatments like 5-fluorouracil in some cases.
• Versatile formulation: Can be prepared as creams, gels, ointments, sprays, patches, and systemic (oral or injectable) dosage forms, allowing patient-friendly administration.
• Improved skin penetration: Utilization of nanoparticles and nanocarriers enhances skin delivery and stability of active ingredients.
• Prophylactic and therapeutic utility: Suitable for both the treatment and prevention of tumor recurrence.
• Broad spectrum: Effective not only on skin tumors but also potentially for a range of epithelial and internal cancers, including in veterinary medicine.
• Potential to overcome resistance issues seen with other therapies by offering a novel mechanism of action targeting polymerase alpha.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to polymerase inhibitors, particularly polymerase alpha inhibitors, and the use thereof in the treatment of cell growth disorders, particularly tumor disorders, preferably actinic keratoses, basal cell carcinomas, and/or spinocellular carcinomas.